[1]
|
E. I. Sokolov, “Diabetes Mellitus and Atherosclerosis,” M. Nauka, 1996, p. 404.
|
[2]
|
P. N. Bodiar, G. M. Denish and O. R. Panasyukova, “Endocrinol Problems,” Vol. 3, 1984, pp. 19-24.
|
[3]
|
A. Araszkiewicz, D. Zozulińska, M. Trepińska, et al., “Inflammatory Markers as Risk Factors for Microangiopathy in Type 1 Diabetic Patients on Functional Intensive Insulin Therapy from the Onset of the Disease,” Diabetes Research and Clinical Practice, Vol. 74, No. 2, 2006, pp. S43-S40.
|
[4]
|
S. G. Kozlov and A. A. Lyakishev, “Dyslipoprotenemias and Their Treatment in Patients with Non-Insulin Dependent Diabetes Mellitus,” Cardiology, Vol. 8, 1999, pp. 59-64.
|
[5]
|
G. Assmann and H. Schulte, “The Prospective Cardiovascular Munster (PROCAM) Study: Prevelance of Hyperlipidemia in Persons with Hypertension and/or Diabetes Mellitus and the Relationship to Coronary Heart Disease,” American Heart Journal, Vol. 116, 1988, pp. 1713-1724.
|
[6]
|
M Laakso, “Epidemiology of Diabetic Dyslipidemia,” Diabetes Reviews, Vol. 3, 1955, pp. 408-422.
|
[7]
|
M. Laakso, E. Voutilainen, H. Sarlund, et al., “Serum lipids and Lipoproteins in Middle-Aged Non-Insulin Dependent Diabetics,” Atherosclerosis,Vol. 56, 1985, pp. 271-281.
|
[8]
|
K. Py?r?l?, M. Laakso and M. Uusitupa, “Diabetes and Atherosclerosis: an Epidemiological View,” Diabetes/ Metabolism Reviews, Vol. 3, 1987, pp. 463-524.
|
[9]
|
G. Steiner, “The Dyslipoproteinemias of Diabetes,” Atherosclerosis, Vol. 110, 1994, pp. 27-33.
|
[10]
|
M. R. Taskinen, “Quantitative and Qualitative Lipoprotein Abnormalities in Diabetes Mellitus,” Diabetes, Vol. 41, No. S2, 1992, pp. 12-17.
|
[11]
|
S. M. Haffner, M. P. Stern, H. P. Haruda, et al., “Cardiovascular Risk Factors in Confirmed Prediabetic Individuals: Does the Clock for Coronary Heart Disease Start Ticking before the Onset of Clinical Diabetes?,” The Journal of the American Medical Association, Vol. 263, 1990, pp. 2893-2898.
|
[12]
|
M. Laakso, T. Ronnemaa, K. Py?r?l?, et al., “Atherosclerosis Vascular Disease and Its Risk Factors on Non-Insulin Dependent Diabetic and Non-Diabetic Subjects in Finland,” Diabetes Care, Vol. 11, 1988, pp. 449-463.
|
[13]
|
J. Stamler, O. Vaccaro, J. D. Neaton, et al., ”The Multiple Risk Factor Intervention Trial Research Group. Diabetes and Other Risk Factors on Coronary Heart Disease and Mortality among Middle-Aged Diabetic Men: A General Population Study,” Diabetes Care, Vol. 16, 1993, pp. 434-444.
|
[14]
|
M. P. Stern, J. K. Patterson, S. M. Haffner, et al., “Lack of Awareness and Treatment of Hyperlipidemia in Type-2 Diabetes in a Community Survey,” The Journal of the American Medical Association, Vol. 262, 1989, pp. 360-364.
|
[15]
|
L. P. Krall, “Clinical Evaluation of Prognosis,” In: A. Marble, P. White, R. F. Bradley and L. P. Krall, Eds., Joslin’s Diabetes Mellitus, Lea and Febiger, Philadelphia, 1973, pp. 211- 254.
|
[16]
|
K. Kornerup, B. G. Nordestgaard, B. Feldt-Rasmussen, et al., “Increased Transvascular Low Density Lipoprotein Transport in Insulin Dependent Diabetes: A Mechanistic Model for Development of Atherosclerosis,” Atherosclerosis, Vol. 170, No. 1, 2003, pp. 163-168.
|
[17]
|
D. P. Wade, B. L. Knight and A. K. Soutar, “Regulation of Low-Density-Lipoprotein-Receptor mRNA by Insulin in Human Hepatoma HepG2 Cells,” European Journal of Biochemistry, Vol. 181, No. 3, 1989, pp. 727-731.
|
[18]
|
G. Ramakrishnan and N. C. Chandra, “Estradiol Regulates Insulin Dependent Stimulation of LDL-Receptor Expression in HepG2 Cells,” Indian Journal of Clinical Biochemistry, Vol. 21, No. 1, pp. 8-14.
|
[19]
|
M. S. Brown and J. L. Goldstein, “A Receptor-Mediated Pathway for Cholesterol Homeostasis,” Science, Vol. 232, No. 4746, 1986, pp. 34-47.
|
[20]
|
S. Swami, C. Sztalryd and F. B. Kraemer, “Effects of Streptozotocin-Induced Diabetes on Low Density Lipoprotein Receptor Expression in Rat Adipose Tissue,” Journal of Lipid Research, Vol. 37, 1996, pp. 229-236.
|
[21]
|
L. Duvillard, F. Galland, E. Florentin, et al., “Cell surface Expression of LDL Receptor is Decreased in Type-2 Diabetic Patients and is Normalized by Insulin Therapy,” Diabetes Care, Vol. 26, No. 5, 2003, pp. 1540-1544.
|
[22]
|
R. J. Havel, H. A. Eder and J. H. Bragdon, “The Distribution and Chemical Composition of Ultracentrifugally Separated Lipoprotein in Human Serum,” Journal of Clinical Investigation, Vol. 34, No. 9, 1955, pp. 1345-1353.
|
[23]
|
G. Ramakrishnan, A. Rana, C. Das and N. C. Chandra, “Study of Low-Density Lipoprotein Receptor Regulation by Oral (Steroid) Contraceptives: Desogestrel, Levonor- gestrel and Ethinyl Estradiol in JEG-3 Cell Line and Placental Tissue,” Contraception, Vol. 76, 2007, pp. 297-305.
|
[24]
|
M. M. Bradford, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,” Analytical Biochemistry, Vol. 72, 1976, pp. 248-254.
|
[25]
|
E. B. Smith and R. S. Slater, “Relationship between Low Density Lipoproteins in Aortic Intima and Serum Lipid Levels,” Lancet, Vol. 1, 1972, pp. 463-469.
|
[26]
|
D. C. Schwenke and T. E. Carew, “Initiation of Atherosclerotic Lesions in Cholesterol-Fed Rabbits, II: Selective Retention of LDL vs Selective Increases in LDL Permeability in Susceptible Sites of Arteries,” Arteriosclerosis, Vol. 9, 1989, pp. 908-918.
|
[27]
|
M. Cybulsky and M. Gimbrone, “Endothelial Expression of a Mononuclear Adhesion Molecule during Atherogenesis,” Science, Vol. 251, 1991, pp. 788-791.
|
[28]
|
K. D. O’Brian, M. D. Allen, T. O. McDonald, et al., “Vascular Cell Adhesion Molecule-1 is Expressed in Human Coronary Atherosclerotic Plaques: Implications for the Mode of Progression of Advanced Coronary Atherosclerosis,” Journal Clinical Investigation, Vol. 92, 1993, pp. 945-951.
|
[29]
|
M. Richardson, S. Hadcock, M. DeReske, et al., “Increased Expression in Vivo of VCAM-1 and E-selectin by the Aortic Endothelium of Normolipidemic and Hyperlipidemic Rabbits,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 14, 1994, pp. 760-769.
|
[30]
|
R. G. Gerrity, “The Role of the Monocyte in Atherogenesis, I: Transition of Blood-Borne Monocytes into Foam Cells in Fatty Lesions,” American Journal of Pathology, Vol. 103, 1981, pp. 181-190.
|
[31]
|
R. Ross, “Atherosclerosis is an Inflammatory Disease”. American Heart Journal, Vol. 138, 1999, pp. S419-S420.
|
[32]
|
M. Navab, J. A. Berliner, A. D. Watson, et al., “The Yin and Yang of Oxidation in the Development of the Fatty Streak. A Review Based on the George Lyman Duff Memorial Lecture,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 16, No. 7, 1994, pp. 831-842.
|
[33]
|
P. M. Henson and D. W. H. Riches, “Modulation of Macrophage Maturation by Cytokines and Lipid Mediators: A Potential Role in Resolution of Pulmonary Inflammation,” Annals of the New York Academy of Sciences, Vol. 725, 2006, pp. 298-308.
|
[34]
|
Y. Liu, L. M. Hulten and O. Wiklund, “Macrophages Isolated from Human Atherosclerotic Plaques Produce IL-8, and Oxysterols may Have a Regulatory Function for IL-8 Production,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 17, 1997, pp. 317-323.
|
[35]
|
J. A. Maries, S. Dahesh, J. Haynes, et al., “Protein-Pro- tein Interaction Affinity Plays a Crucial Role in Controlling the sho1p-Mediated Signal Transduction Pathway in Yeast,” Molecular Cell, Vol. 14, 2004, pp. 813-823.
|
[36]
|
Y. C. Chen, H. C. Chen and J. M. Yang, “A 3D-Domain Annoted Protein-Protein Interaction Database,” Genome Informatics, Vol. 17, No. 2, 2006, pp. 206-215.
|